Clinical trial SELINDA
A Phase IB study of oral selinexor in adult patients with relapsed/refractory B-cell lymphoma receiving R-DHAOx or R-GDP
| Cancers | |
|---|---|
| Organ | Non-Hodgkin lymphoma |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Non |
| Sponsor | Lysarc |
| EudraCT Identifier | 2015-005612-15 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02741388 |
| Inclusion criteria | Eligible to receive R-GDP - with at least one but no more than two lines therapies - no previous treatment with Selinexor |
| Last update |